Fred Wiklund, Bright Peak Therapeutics CEO

Piv­ot­ing to ‘ADC-like’ ap­proach, Ver­sant-backed start­up gets $90M Se­ries C

Bright Peak Ther­a­peu­tics an­nounced a $90 mil­lion Se­ries C, though its sci­en­tif­ic fo­cus and pipeline looks dif­fer­ent than it did three years ago.

Short­ly af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.